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The MBOAT7 variant rs641738 alters hepatic phosphatidylinositols
and increases severity of non-alcoholic fatty liver disease in humans
To the Editor:
We have recently shown in 125 subjects that insulin resistance
and the PNPLA3 I148M gene variant, two common risk factors
of NAFLD, are characterized with markedly different content
and composition of lipids in the human liver [1]. In 2015, a vari-
ant in membrane bound O-acyltransferase domain containing 7
(MBOAT7) at rs641738 was discovered to increase the risk of alco-
hol-related cirrhosis [2]. This variant was also shown to increase
the risk of steatosis and histologic liver damage in NAFLD, inde-
pendent of obesity [3]. The variant allele was common with a
population prevalence of 58–67% and characterized by decreased
hepatic gene and protein expression of MBOAT7 [3]. MBOAT7 is
also known as lysophosphatidylinositol acyltransferase 1 (LPIAT1),
which catalyzes acyl-chain remodeling of phosphatidylinositols
(PIs) [4]. Consistent with this function, plasma lipidomics analy-
ses showed that amongst various lipid classes (triglycerides, cho-
lesteryl esters, phospholipids, ceramides and sphingomyelins),
only concentrations of PIs were altered [3]. Specifically, plasma
concentrations of PI (36:4), PI (38:3) and PI (38:5) were
decreased in proportion to the number ofMBOAT7 variant alleles,
while most other PIs were increased [3].
To study effects of genetic variation in MBOAT7 on human
liver histology and lipidome, we genotyped the subjects in our
previous study at rs641738 [1]. The subjects were consecutive
patients undergoing bariatric surgery recruited using the inclu-
sion and exclusion criteria described in [1]. The liver lipidome
was analyzed using ultra-high performance liquid and gas chro-
matography combined with mass spectrometry and histology
as described [1]. DNA was available from 115 subjects (age
48.0 ± 0.8 years, BMI 45.4 ± 0.5 kg/m2, 67 % women), who were
divided into three groups based on their MBOAT7 genotype at
rs641738 (n = 35 for CC, n = 60 for CT, n = 20 for TT).
The MBOAT7 genotype groups were similar with respect to
age, gender, BMI, waist circumference, PNPLA3 I148M and
TM6SF2 E167K genotypes (data not shown).
Steatosis (% of grades 0/1/2/3 were 23/60/3/14, 25/62/12/2
and 20/55/25/0, p = 0.03 in CC, CT and TT groups) and necroin-
flammatory (% of grades 0/1/2/3 were 74/26/0/0, 87/13/0/0 and
60/35/0/5, p = 0.04) grades differed significantly between the
MBOAT7 groups. The prevalence of significant fibrosis (F2-4)
increased with number of MBOAT7 variant alleles (0 vs. 5 vs. 25
%, p = 0.001, Fig. 1). Of 7 different PIs in the human liver, PI
(36:4) and PI (38:3), i.e., the same PIs as in the plasma in the
study of Mancina and Dongiovanni et al. [3], decreased signifi-
cantly as a function of the number of MBOAT7 variant alleles,
while the concentration of PI (40:5) increased (Fig. 1). All other
lipid classes in the human liver (triglycerides, cholesterol esters,
ceramides, sphingomyelins, hexosylceramides, phospholipids,
and free fatty acids) were similar between the groups (data not
shown). Fasting insulin (13.7 [8.4–17.1], 11.2 [6.5–18.3] and
12.3 [7.0–18.8] mU/L in CC, CT and TT groups), glucose (5.9
[5.0–6.6], 5.8 [5.4–6.6] and 5.7 [5.1–6.1] mmol/L), triglycerides
(1.24 [1.06–1.55], 1.29 [0.91–1.69] and 1.08 [1.00–1.59] mmol/L),
HDL (1.15 [0.98–1.33], 1.09 [0.93–1.38] and 0.98 [0.86–1.13]
mmol/L) and low density lipoprotein (2.5 [1.9–3.4], 2.3 [1.7–
2.9] and 2.4 [1.5–3.5] mmol/L) cholesterol concentrations were
similar between the groups.
We thus replicate effects of the MBOAT7 variant rs641738 on
human liver histology with respect to steatosis and necroinflam-
mation, and an increased prevalence of significant fibrosis [3].
The latter is the key predictor of overall mortality, liver trans-
plantation, and liver-related events [5,6].
PIs are lipids, which regulate membrane dynamics and signal
transduction pathways [4]. They consist of a glycerol backbone
and two variable fatty acyl-chains, of which one is predominantly
saturated and the other polyunsaturated [4]. MBOAT7 partici-
pates in acyl-chain remodeling of PIs in the Lands’ cycle, in which
it incorporates a polyunsaturated fatty acyl-chain into a PI [4]. In
mice, knockout of LPIAT1, i.e. MBOAT7, affects concentrations of
hepatic polyunsaturated PIs [7]. Another enzyme of the MBOAT
family, MBOAT5, participates in the acyl-chain remodeling of
phosphatidylcholines [8]. Knockout of MBOAT5 in mice decreases
arachidonic acid-containing phosphatidylcholines in the liver and
increases the risk of hepatic steatosis and inflammation [8].
MBOAT7 deficiency is thus predicted to increase free polyunsat-
urated fatty acids [9] and their proinflammatory metabolites,
which are increased in plasma of subjects with non-alcoholic
steatohepatitis [10]. Detailed understanding of the mechanisms
via which the altered hepatic phosphatidylinositol metabolism
leads to liver fibrosis are thus of considerable interest.
In conclusion, we confirm that the common variant in
MBOAT7 rs641738 associates with histologic liver damage, partic-
ularly significant fibrosis. We extend previous data by showing
that altered polyunsaturated PI metabolism characterizes the
human liver in carriers of the MBOAT7 variant. These data are
consistent with recent data in plasma and a role for MBOAT7 in
hepatic phosphatidylinositol remodeling [3].
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Fig. 1. Prevalence of significant fibrosis and hepatic concentrations of
phosphatidylinositols PI (40:5), PI (36:4), and PI (38:3) in groups according
to the MBOAT7 genotype at rs641738. Data are in % and median (25th–75th
percentile), and were tested using Pearson’s v2 test, Kolmogorov-Smirnov test
and Mann-Whitney U test, as appropriate. ⁄p <0.05, ⁄⁄p <0.01.
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